Trial Profile
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms EMERGE
- Sponsors Celldex Therapeutics Inc
- 27 Sep 2015 Results of post-hoc analysis (n=328) presented at the ASCO - Breast Cancer Symposium 2015
- 06 Apr 2015 According to a Celldex Therapeutics media release, the data from this study supported the initiation of the phase 2 METRIC study. (See CT profile 700239414)
- 06 Apr 2015 Results published in a Celldex Therapeutics media release.